RESUMOPara verificar a variabilidade do controle glicêmico em um estudo não controlado de diabéticos durante um ano de acompanhamento, nós avaliamos retrospectivamente 113 pacientes diabéticos. Com os valores das HBA 1c (hemoglobina glicada) dosadas em 1998 calculamos um índice de controle que foi associado à idade, duração do diabetes, IMC e dose de insulina. A HBA 1c foi maior em pacientes DM1 do que DM2, respectivamente [7,9 (4,4-13,3) vs. 7,0 (4,4-13,4 ) diminuição e 5 pacientes (5,6%) mantiveram o mesmo valor, sem diferença entre DM1 e DM2 (p= 0,77). Observamos diferença na HBA 1c e tempo de duração de diabetes entre os pacientes com DM2 que tratavam com dieta, hipoglicemiante oral, terapia combinada e monoterapia com insulina, respectivamente (5,4±0,5 vs. 6,3±1,3 vs. 7,6±1,4 vs. 8,4±2,0%; p= 0,001) e (8,5±9,9 vs. 5,3±4,2 vs. 14,1±9,6 vs. 16,9±8,1 anos; p= 0,003). O coeficiente de variação intraindividual da HBA 1c foi de 11,6±7,4% (p= 0,0000), sendo de 12,8±7,6% (p= 0,0000) em DM1 e 10,4±7,2% em DM2 (p= 0,0000) sem diferença entre ambos. Concluímos que em nossa amostra a maioria dos pacientes manteve um bom controle apesar da variabilidade intraindividual e da dificuldade em normalizar os níveis de HBA 1c. ABSTRACTTo evaluate the variability of glicemic control in diabetic patients followed during one year, we conducted a retrospective study in which the record data of 113 diabetic patients were analyzed. The value of HBA 1c (glycated hemoglobin) measured during a year were registered and an index of glicemic control was calculated. This index was associated with duration of diabetes, BMI and dose of insulin. HBA 1c were higher in type 1 diabetes than type 2, respectively, [7.9 (4.4-13.3) vs. 7.0 (4.4-13.4)%; p= 0.007]. In 90 patients with at least two HBA 1c measurements, 68 (75.6%) had no change in glicemic control: 51 (76.1%) had good, 8 (11.1%) regular and 9 (11.9%) poor control. None of them sustained all the HBA 1c in the normal range: 26 (28.9%) had at least one normal HBA 1c value. In general group, 44 patients (48.9%) showed increase, 41 (45.6%) decreased and 5 (5.6%) remained with the same level of HBA 1c , without difference between DM1 and DM2 (p= 0,77). A difference in HBA 1c and diabetes duration among patients with DM2 treated with diet, oral hipoglycemic agents, combined therapy and monotherapy with insulin, was noted respectively (5.4±0.5 vs. 6.3±1.3 vs. 7.6±1.4 vs. 8.4±2.0%; p= 0.001) and (8.5±9.9 vs. 5.3±4.2 vs. 14.1±9.6 vs. 16.9±8.1 years; p= 0,003). The intraindividual coefficient of variation of HBA 1c was 11.6±7.4% (p= 0.0000)
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.